Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H24O2.C2H6NO3S.K |
Molecular Weight | 363.555 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[K+].NCCS([O-])(=O)=O.CCCCCCCCCCCC(O)=O
InChI
InChIKey=YXUKIOYEWGMHBJ-UHFFFAOYSA-M
InChI=1S/C12H24O2.C2H7NO3S.K/c1-2-3-4-5-6-7-8-9-10-11-12(13)14;3-1-2-7(4,5)6;/h2-11H2,1H3,(H,13,14);1-3H2,(H,4,5,6);/q;;+1/p-1
Molecular Formula | C12H24O2 |
Molecular Weight | 200.3178 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | K |
Molecular Weight | 39.0983 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C2H6NO3S |
Molecular Weight | 124.139 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://doi.org/10.1016/S0378-1097(03)00611-6Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/3676193 | http://www.medscape.com/viewarticle/804080 | https://www.ncbi.nlm.nih.gov/pubmed/21334852 |
https://www.ncbi.nlm.nih.gov/pubmed/26208967
Sources: https://doi.org/10.1016/S0378-1097(03)00611-6
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/3676193 | http://www.medscape.com/viewarticle/804080 | https://www.ncbi.nlm.nih.gov/pubmed/21334852 |
https://www.ncbi.nlm.nih.gov/pubmed/26208967
Taurine is a semi-essential amino acid and is not incorporated into proteins. Taurine is considered conditionally essential because it cannot be synthesized by infants younger than 4-6 weeks, and it may not be adequately synthesized in patients receiving long-term parenteral nutrition and patients with short-term hypermetabolic conditions. In mammalian tissues, taurine is ubiquitous and is the most abundant free amino acid in the heart, retina, skeletal muscle, brain, and leukocytes. Taurin occurs naturally in fish and meat. The mean daily intake from omnivore diets was determined to be around 58 mg. Taurine is a component of energy drinks, with many contain 1000 mg per serving. In medicine, taurine supplementation demonstrated efficacy in relieving symptoms of heart failure, hepatitis, hypertension and psychotic disorder. Taurine exerts many physiological functions, including membrane stabilization, osmoregulation and cytoprotective effects, antioxidant and anti-inflammatory actions as well as modulation of intracellular calcium concentration and ion channel function. In addition taurine may control muscle metabolism and gene expression, through yet unclear mechanisms. The cellular and biochemical mechanisms mediating the actions of taurine are not fully known.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1907607 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23637894 |
|||
Target ID: CHEMBL3392921 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9279812 |
406.0 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TAURINE Approved UseTaking 2-3 grams of taurine by mouth one to two times daily for 6-8 weeks seems to improve heart function and symptoms in patients with moderate heart failure to severe heart failure. Some patients with severe heart failure rapidly improve from NYHA class IV to II after 4-8 weeks of treatment. Improvement seems to continue for as long as taurine treatment is continued, up to one year. |
|||
Palliative | TAURINE Approved UseTaking 1.5-4 grams of taurine daily for up to 3 months improves liver function in people with hepatitis. |
|||
Preventing | URSA Complex Approved UseTaurine is a component of energy drinks used for relieving of fatigue |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[A study on the mechanism of taurine postponing the aging process of human fetal brain neural cells]. | 1997 Mar |
|
Sodium nitroprusside-induced seizure and taurine release from rat hippocampus. | 2000 |
|
Calcium-mediated transductive systems and functionally active gap junctions in astrocyte-like GL15 cells. | 2001 |
|
Two years' experience with Dialock and CLS (a new antimicrobial lock solution). | 2001 |
|
Zinc and the eye. | 2001 Apr |
|
Conditioned nutritional deficiencies in the cardiomyopathic hamster heart. | 2001 Apr |
|
Transport of L-carnitine in isolated cerebral cortex neurons. | 2001 Apr |
|
Depletion of taurine in experimental diabetic neuropathy: implications for nerve metabolic, vascular, and functional deficits. | 2001 Apr |
|
Fertilizability and developmental capacity of bovine oocytes cultured individually in a chemically defined maturation medium. | 2001 Apr 15 |
|
Inhibition of the myeloperoxidase chlorinating activity by non-steroidal anti-inflammatory drugs investigated with a human recombinant enzyme. | 2001 Apr 6 |
|
Mast cell numbers in the young rat thalamus: a search for control factors. | 2001 Aug |
|
The use of 1H magnetic resonance spectroscopy in inflammatory bowel diseases: distinguishing ulcerative colitis from Crohn's disease. | 2001 Feb |
|
Hamster sperm glycine receptor: evidence for its presence and involvement in the acrosome reaction. | 2001 Feb |
|
Influence of protein kinases on the osmosensitive release of taurine from cerebellar granule neurons. | 2001 Feb |
|
Can this pill stop you from hitting the bottle? | 2001 Feb 12 |
|
[Effect of taurine on the microvessel exchange function and adrenergic response of veins and arteries in the cat skeletal muscle]. | 2001 Jan |
|
MR diffusion imaging and 1H spectroscopy in a child with medulloblastoma. A case report. | 2001 Jan |
|
Studies on the effects of lactate transport inhibition, pyruvate, glucose and glutamine on amino acid, lactate and glucose release from the ischemic rat cerebral cortex. | 2001 Jan |
|
Nucleoside transport inhibition in ischemic myocardium results in enhanced taurine efflux. | 2001 Jan 5 |
|
Taurine modulates catalase, aldehyde dehydrogenase, and ethanol elimination rates in rat brain. | 2001 Jan-Feb |
|
The effect of taurine depletion by beta-alanine treatment on the susceptibility to ethanol-induced hepatic dysfunction in rats. | 2001 Jan-Feb |
|
Dietary taurine manipulations in aged male Fischer 344 rat tissue: taurine concentration, taurine biosynthesis, and oxidative markers. | 2001 Jul 1 |
|
Taurine modulates arginine vasopressin-mediated regulation of renal function. | 2001 Jun |
|
17 beta-estradiol protects neurons from ischemic damage and attenuates accumulation of extracellular excitatory amino acids. | 2001 Jun |
|
Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells. | 2001 Jun 1 |
|
Reactive nitrogen oxygen species metabolize N-acetylbenzidine. | 2001 Mar |
|
Hypocholesterolemic effect of bile acid sulfonate analogs in hamsters. | 2001 Mar |
|
Production of brominating intermediates by myeloperoxidase. A transhalogenation pathway for generating mutagenic nucleobases during inflammation. | 2001 Mar 16 |
|
Intrathecal magnesium sulfate attenuates algogenic behavior and spinal amino acids release after kainic acid receptor activation in rats. | 2001 Mar 30 |
|
High glucose inhibits renal proximal tubule cell proliferation and involves PKC, oxidative stress, and TGF-beta 1. | 2001 May |
|
Cysteine regulates expression of cysteine dioxygenase and gamma-glutamylcysteine synthetase in cultured rat hepatocytes. | 2001 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3676193
Taurin occurs naturally in fish and meat. The mean daily intake from omnivore diets was determined to be around 58 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9279812
Agonist properties of taurine on glycine receptor of supraoptic magnocellular neurones acutely dissociated from adult rats, using whole-cell voltage clamp. Responses to 1 mM taurine were blocked by strychnine but not by gabazine and showed no additivity with glycine-induced currents, indicating selective activation of glycine receptors.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 17 12:34:19 UTC 2022
by
admin
on
Sat Dec 17 12:34:19 UTC 2022
|
Record UNII |
GQK0L6ZDHA
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
76963160
Created by
admin on Sat Dec 17 12:34:19 UTC 2022 , Edited by admin on Sat Dec 17 12:34:19 UTC 2022
|
PRIMARY | |||
|
GQK0L6ZDHA
Created by
admin on Sat Dec 17 12:34:19 UTC 2022 , Edited by admin on Sat Dec 17 12:34:19 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |